SPOTLIGHT -
EP. 1: Introduction and Overview of CRPC Treatment Challenges
EP. 2: New Treatment Options for Advanced Prostate Cancer
EP. 3: New Investigational Treatments in Prostate Cancer
EP. 4: Case Study: Postoperative Treatment of Prostate Cancer
EP. 5: Case Study: Initiating Androgen Deprivation Therapy
EP. 6: Case Study: Managing Bone Health Following ADT
EP. 7: Case Study: Treating Asymptomatic mCRPC
EP. 8: Dr. George on Radium-223 for Patients With mCRPC, Part I
EP. 9: Dr. George on Radium-223 for Patients With mCRPC, Part II
EP. 10: Dr. Finkelstein Describes the Phase III ALSYMPCA Trial
EP. 11: Dr. Finkelstein Discusses the Safety Profile of Radium-223
EP. 12: Dr. Finkelstein Discusses Radium-223 Reimbursement
EP. 13: Dr. Finkelstein Summarizes the Development of Radium-223
EP. 14: Utilizing Early Imaging to Detect Metastatic CRPC
EP. 15: Treatment With Sipuleucel-T in Advanced Prostate Cancer
EP. 16: Case Study: Minimally Symptomatic mCRPC
EP. 17: Case Study: Managing Symptomatic mCRPC
EP. 18: Conclusion: Final Thoughts on Treating mCRPC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
